Zeltia Group

Zeltia: Report at 31 December 2005

    Madrid (ots/PRNewswire) -


    - Capital increase at Zeltia. The placement of 10.75 million new shares among qualified international investors raised 65 million euro

    - R&D expenditure up 24%

    - Net revenues in 2005: 72 million euro

    - Net cash position at 31 December 2005: 93 million euro net of short-term financial debt and 51 million euro net of total financial debt


    - Yondelis(R):

    - Phase III pivotal trial on ovarian cancer commenced

    - Recruitment for the pivotal randomised trial on soft-tissue sarcoma was completed

    - Aplidin(R):

    - Phase II studies on prostate and bladder cancer commenced

    - Combination studies with other chemotherapy agents commenced

    - Zalypsis(R), PharmaMar's fifth compound to reach clinical trials

    - PM02734 is PharmaMar's sixth compound to reach clinical trials


    - Launched a full range of Xylazel-brand wood protecting paints and varnishes.

    - Conclusion of licensing and marketing agreement with ICI.

      Isabel Lozano
      Chief Executive Officer
      C/ Reyes, 1.
      Colmenar Viejo Madrid
      Telephone +34-91-846-60-00
      Catherine Moukheibir
      Head of Capital Market Strategy
      ZELTIA, S.A.
      José Abascal, 2. Madrid
      Telephone +34-91-444-45-00
      Ma Luisa de Francia
      Chief Financial Officer
      ZELTIA, S.A.
      José Abascal, 2. Madrid
      Telephone +34-91-444-45-00

    For a copy of the full results, please refer to www.zeltia.com

ots Originaltext: Zeltia Group
Im Internet recherchierbar: http://www.presseportal.ch

Isabel Lozano, Chief Executive Officer, PHARMAMAR, S.A., C/ Reyes,
1., Colmenar Viejo, Madrid, Telephone +34-91-846-60-00; Catherine
Moukheibir, Head of Capital Market Strategy, ZELTIA, S.A., José
Abascal, 2. Madrid, Telephone +34-91-444-45-00; Ma Luisa de Francia,
Chief Financial Officer, ZELTIA, S.A., José Abascal, 2. Madrid,
Telephone +34-91-444-45-00

Weitere Meldungen: Zeltia Group

Das könnte Sie auch interessieren: